Investment Summary

Ampersand Capital Partners Invests In Alliance Pharma

On November 18, 2021, growth capital firm Ampersand Capital Partners invested in life science company Alliance Pharma

Investment Highlights
  • This is Ampersand Capital Partners’ 31st transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 57th transaction in the United States.
  • This is Ampersand Capital Partners’ 1st transaction in Pennsylvania.

Investment Summary
Date 2021-11-18
Target Alliance Pharma
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type Growth Capital

Target

Alliance Pharma

Malvern, Pennsylvania, United States
website
Alliance Pharma is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance Pharma was founded in 2008 and is headquartered in Malvern, Pennsylvania.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 65 of 79
Sector (Life Science) 31 of 39
Type (Growth Capital) 19 of 26
State (Pennsylvania) 1 of 1
Country (United States) 57 of 65
Year (2021) 8 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-17 Leinco

St. Louis, Missouri, United States

Leinco is a biotechnology company that is engaged in the manufacturer of early discovery research products including antibodies, recombinant proteins, ELISA kits, second step reagents, and other life sciences products. Leinco was founded in 1992 and is based in St. Louis, Missouri.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-07 AnaBios

San Diego, California, United States

AnaBios is a preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to measure drug activity directly in human tissue. AnaBios is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal